Last reviewed · How we verify
Neofordex®
Neofordex is a selective glucocorticoid receptor agonist that modulates immune and inflammatory responses with reduced systemic side effects compared to conventional corticosteroids.
Neofordex is a selective glucocorticoid receptor agonist that modulates immune and inflammatory responses with reduced systemic side effects compared to conventional corticosteroids. Used for Acute graft-versus-host disease (aGVHD).
At a glance
| Generic name | Neofordex® |
|---|---|
| Also known as | Dexamethasone |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Selective glucocorticoid receptor agonist |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Inflammation |
| Phase | Phase 3 |
Mechanism of action
Neofordex selectively activates glucocorticoid receptors to suppress inflammatory and immune responses. By targeting glucocorticoid receptor signaling pathways with improved selectivity, it aims to provide anti-inflammatory benefits while minimizing adverse effects associated with traditional broad-spectrum corticosteroids.
Approved indications
- Acute graft-versus-host disease (aGVHD)
Common side effects
- Infection
- Hyperglycemia
- Hypertension
- Immunosuppression-related adverse events
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |